Recent years have seen a shift in psychiatry research from a focus on discrete diagnostic categories to a more transdiagnostic and neurobiologicallly informed understanding of patient symptoms. However, this intellectual shift has yet to translate into new treatment approaches. I will describe how how Boehringer Ingelheim is working towards greater precision in psychiatry, with a focus on areas of particular unmet need for patients. I will also outline how BI collaborates with external partners, providing insights into how industry and academia may work together for mutual benefit.

To join via Zoom, please use the link below:

zoom.us/j/94457342362?pwd=bCtoSXlaSjRNejBMaXluSTMwVWdVQT09
Meeting ID: 944 5734 2362
Passcode: 051588